An open-label review was completed in 2016 in the UK to research the feasibility, safety and efficacy of psilocybin in managing people with unipolar treatment-resistant depression with promising final results; although the review was tiny and included only twelve people, seven of Those people people satisfied formal criteria for remission one parti